Versiti Clinical Trials Services Partners with 4D Path to Accelerate Personalized Cancer Treatment Development
Versiti Clinical Trials Services (VCTS) has launched a partnership with 4D Path to bring cutting-edge treatment predictive biomarker technology to researchers developing lifesaving, personalized cancer treatments. The collaboration makes 4D Path's Q-Plasia OncoReader (QPOR™) platform available to pharmaceutical companies and clinical research organizations working with VCTS, giving them powerful new tools to understand how individual cancers respond to treatment.
4D Path Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Predictive Biomarkers for an Antibody Drug Conjugate Program
4D Path, a company dedicated to personalizing cancer care through a novel, physics-informed approach to predicting tumor response to therapy, today announced a collaboration with Daiichi Sankyo (TSE: 4568) to develop next-generation predictive biomarkers in an antibody drug conjugate (ADC) clinical development program.
